Vivekananda M. Vrudhula
Research Subjects
Vivekananda M. Vrudhula has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Bireshwar Dasgupta
Bristol‐Myers Squibb, Research and Development, 5 Research Parkway Wallingford CT 06492 USA
3 shared publicationsChristopher G. Boissard
Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, Connecticut 06492
2 shared publicationsGene M. Dubowchik
Molecular Sciences and Candidate Optimization, Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492, United States
2 shared publicationsJohn E. Macor
Molecular Sciences and Candidate Optimization, Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492, United States
2 shared publicationsPeter D. Senter
2 shared publicationsValentin K. Gribkoff
Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, Connecticut 06492
2 shared publications
Latest Publications
- 1 June 2014
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 24 (12) , 2744-2748
Serendipitous oxidation product of BIBN4096BS: A potent CGRP receptor antagonist
- 1 June 2014
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 24 (12) , 2744-2748
Serendipitous oxidation product of BIBN4096BS: A potent CGRP receptor antagonist
- 1 March 2010
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (6) , 1905-1909
Design, synthesis and evaluation of constrained tetrahydroimidazopyrimidine derivatives as antagonists of corticotropin-releasing factor type 1 receptor (CRF1R)
- 1 March 2010
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (6) , 1905-1909
Design, synthesis and evaluation of constrained tetrahydroimidazopyrimidine derivatives as antagonists of corticotropin-releasing factor type 1 receptor (CRF1R)
- 3 February 2007
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 50 (5) , 1050-1057
Atropisomeric 3-(β-hydroxyethyl)-4-arylquinolin-2-ones as Maxi-K Potassium Channel Openers
The synthesis of a series of 3-β-hydroxyethyl-4-arylquinolin-2-ones is described. These compounds contain hydrophilic and hydrophobic substituents ortho to the phenolic OH in the C ring of the quinolinone. Electrophysiological evaluation of the panel of compounds revealed that 11 and 16 with an unbranched ortho substituent retain activity as maxi-K ion channel openers. Members of this series of compounds can exist as stable atropisomers. Calculated estimates of the energy barrier for rotation around the aryl−aryl single bond in 3 is 31 kcal/mol. The atropisomers of (±)-3, (±)-4, and (±)-11 were separated by chiral HPLC and tested for their effect on maxi-K mediated outward current in hSlo injected X. laevis oocytes. The (−) isomer in each case was found to be more active than the corresponding (+) isomer, suggesting that the ion channel exhibits stereoselective activation. X-ray crystallographic structures of (+)-3 and (+)-11 were determined. Evaluation of the stability of (−)-3 at 80 °C in n-butanol indicated a 19.6% conversion to (+)-3 over 72 h. In human serum at 37 °C (−)-3 did not racemize over the course of the 30 h study.
- 3 February 2007
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 50 (5) , 1050-1057
Atropisomeric 3-(β-hydroxyethyl)-4-arylquinolin-2-ones as Maxi-K Potassium Channel Openers
The synthesis of a series of 3-β-hydroxyethyl-4-arylquinolin-2-ones is described. These compounds contain hydrophilic and hydrophobic substituents ortho to the phenolic OH in the C ring of the quinolinone. Electrophysiological evaluation of the panel of compounds revealed that 11 and 16 with an unbranched ortho substituent retain activity as maxi-K ion channel openers. Members of this series of compounds can exist as stable atropisomers. Calculated estimates of the energy barrier for rotation around the aryl−aryl single bond in 3 is 31 kcal/mol. The atropisomers of (±)-3, (±)-4, and (±)-11 were separated by chiral HPLC and tested for their effect on maxi-K mediated outward current in hSlo injected X. laevis oocytes. The (−) isomer in each case was found to be more active than the corresponding (+) isomer, suggesting that the ion channel exhibits stereoselective activation. X-ray crystallographic structures of (+)-3 and (+)-11 were determined. Evaluation of the stability of (−)-3 at 80 °C in n-butanol indicated a 19.6% conversion to (+)-3 over 72 h. In human serum at 37 °C (−)-3 did not racemize over the course of the 30 h study.
- 1 October 2005
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 15 (19) , 4286-4290
Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes
- 1 October 2005
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 15 (19) , 4286-4290
Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes
- 1 February 2003
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (3) , 539-542
Cephalosporin prodrugs of paclitaxel for immunologically specific activation by L-49-sFv-β-Lactamase fusion protein
- 1 February 2003
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (3) , 539-542
Cephalosporin prodrugs of paclitaxel for immunologically specific activation by L-49-sFv-β-Lactamase fusion protein
- 1 January 1995
- Published by Taylor & Francis in Drug Delivery
- Vol. 2 (2) , 110-116
Sulfated etoposide and nitrogen mustard prodrugs and their activation by streptomyces arylsulfatase
Etoposide sulfate (ES) and p-di-2-chloroethylaminophenyl sulfate (CAPS) were designed as nontoxic anticancer prodrugs of etoposide and p-di-2-chloroethylaminophenol (CAP) that could be activated on tumor cell surfaces by monoclonal antibody (mAb)-arylsulfatase conjugates. In vitro assays indicated that CAPS and ES were nontoxic to the H2981 human lung adenocarcinoma cell line, while etoposide and CAP had IC50 values of 1–2 μM. Several commercially available arylsulfatases, as well as the arylsulfatases from human liver and urine, were either unable or poorly able to effect the hydrolysis of ES and CAPS. In contrast, arylsulfatase from Streptomyces (SAS) hydrolyzed ES and CAPS with specific activities of 3.0 and 4.8 μmol/min/ mg, respectively. SAS was conjugated to the L6 mono-clonal antibody and was able to activate ES in an immunologically specific manner on H2981 cells (L6 antigen positive). ES and CAPS were stable in mouse serum and were at least 9–13 times less toxic to mice on a molar basis than etoposide and CAP. Thus, ES and CAPS may have significant potential as prodrugs for site-specific activation by mAb-SAS conjugates.
- 1 January 1995
- Published by Taylor & Francis in Drug Delivery
- Vol. 2 (2) , 110-116
Sulfated etoposide and nitrogen mustard prodrugs and their activation by streptomyces arylsulfatase
Etoposide sulfate (ES) and p-di-2-chloroethylaminophenyl sulfate (CAPS) were designed as nontoxic anticancer prodrugs of etoposide and p-di-2-chloroethylaminophenol (CAP) that could be activated on tumor cell surfaces by monoclonal antibody (mAb)-arylsulfatase conjugates. In vitro assays indicated that CAPS and ES were nontoxic to the H2981 human lung adenocarcinoma cell line, while etoposide and CAP had IC50 values of 1–2 μM. Several commercially available arylsulfatases, as well as the arylsulfatases from human liver and urine, were either unable or poorly able to effect the hydrolysis of ES and CAPS. In contrast, arylsulfatase from Streptomyces (SAS) hydrolyzed ES and CAPS with specific activities of 3.0 and 4.8 μmol/min/ mg, respectively. SAS was conjugated to the L6 mono-clonal antibody and was able to activate ES in an immunologically specific manner on H2981 cells (L6 antigen positive). ES and CAPS were stable in mouse serum and were at least 9–13 times less toxic to mice on a molar basis than etoposide and CAP. Thus, ES and CAPS may have significant potential as prodrugs for site-specific activation by mAb-SAS conjugates.